<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543527</url>
  </required_header>
  <id_info>
    <org_study_id>START_001</org_study_id>
    <nct_id>NCT03543527</nct_id>
  </id_info>
  <brief_title>Study of Refractory and/or Relapsing TAkayasu aRTeritis</brief_title>
  <acronym>START</acronym>
  <official_title>Observational Multicenter Study of Refractory and/or Relapsing Takayasu Arteritis START: Study of Refractory and/or Relapsing TAkayasu aRTeritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Takayasu arteritis (TA) is a vasculitis of unknown origin, resulting in progressive
      thickening and stenosis of large and medium arteries (the aorta and its major branches, and
      the pulmonary arteries). First line therapy of TA consists of high dose corticosteroids (CS)
      (Mukhtyar et al, 2009). Between 20 and 50% of cases respond to CS alone, with subsequent
      resolution of symptoms and stabilization of vascular abnormalities (Shelhamer et al, 1985;
      Maksimowicz-McKinnon et al, 2007). Although second-line agents (methotrexate, azathioprine,
      mycophenolate mofetil, cyclophosphamide) may result in initial remission, relapses remain
      common when prednisone is tapered (Maksimowicz-McKinnon et al, 2007). Thus, 50% of
      CS-resistant or relapsing TA patients may achieve sustained remission with the addition of
      methotrexate (Hoffman et al, 1994). During the last decade, biologics such as anti-tumor
      necrosis factor alpha (anti-TNFα) and anti-interleukin-6 (anti-IL-6) have been used as
      third-line treatment in refractory or relapsing TA. Almost 90% of CS-methotrexate resistant
      TA cases responded to infliximab, an anti-TNFα, and sustained remission was obtained in 37 to
      76% of the cases (Schmidt et al, 2012; Comarmond et al, 2012; Mekinian et al, 2012).
      Tocilizumab, an anti-IL-6 has given similar results with 68% of sustained remission in
      refractory TA (Abisror et al, 2013). Irrespective of classical cardiovascular risk factors,
      the systemic inflammation and CS use play a pivotal role in the occurrence of cardiovascular
      thrombotic events (CVEs) (Roubille et al, 2015). As CVEs overlap with TA complications it is
      primordial to drastically taper CS in that vasculitis. We therefore aim to analyses
      prospectively the long term outcome of refractory/relapsing TA patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with prednisone ≤ 0.1mg/kg per day and sustained inactive disease.</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with prednisone ≤ 0.1mg/kg per day and sustained inactive disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of relapse</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of relapse</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of treatment failure</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of treatment failure</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of revascularization procedures</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of revascularization procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of revascularization procedures</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of revascularization procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events of treatments received</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of adverse events of treatments received</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events of treatments received</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of adverse events of treatments received</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Systemic Vasculitis</condition>
  <condition>Arteritis, Takayasu</condition>
  <condition>Arteritis</condition>
  <arm_group>
    <arm_group_label>Takayashu</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>Takayashu</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Takayasu Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Takayasu arteritis according to the international criteria of the
             American College of Rheumatology (ACR) (Arend et al, 1990) and/or Ishikawa criteria
             modified by Sharma.

          -  Active disease according to the international criteria of the National Institute of
             Health (NIH) (Kerr et al, 1994)

          -  Able and willing to give informed consent and comply with the requirements of the
             study protocol

        Exclusion Criteria:

          -  Aortitis of other cause (i.e. infectious, ANCA vasculitis, histiocytosis, cancer..)

          -  Lack of affiliation to a social security benefit plan (as a beneficiary or assignee)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David SAADOUN, MD PhD</last_name>
    <phone>142178088</phone>
    <phone_ext>+33</phone_ext>
    <email>david.saadoun@psl.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu RESCHE-RIGON, MD PhD</last_name>
    <phone>142499742</phone>
    <phone_ext>+33</phone_ext>
    <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>La pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Saadoun, MD PhD</last_name>
      <phone>142178009</phone>
      <phone_ext>+33</phone_ext>
      <email>dsaadoun@wanadoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

